DoD FY15 Peer Reviewed Alzheimer’s Convergence Science Research Award

archived

The Peer Reviewed Alzheimer’s Research Program (PRARP) Convergence Science Research Award (CSRA) mechanism was first offered in FY12. Since then, 92 CSRA applications have been received, and 22 have been recommended for funding. The intent of the FY15 CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission. The research impact will benefit the military, Veteran, and civilian communities. The CSRA is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline who seek to bring their expertise to address the PRARP’s mission. However, as part of the application, the PI should demonstrate that the study team has experience in both TBI and AD research. Preliminary data, while not required, is encouraged. FY15 CSRA Overarching Challenges: This CSRA funding opportunity requires applications to address one or more of the following Overarching Challenges: Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD for the military and Veteran communities. Paucity of Clinical Studies: The paucity of clinical or epidemiological studies to examine the interrelationship between TBI and subsequent AD for the military and Veteran communities. Diagnostic Technologies, Tests, or Devices: The need for technologies, tests, or devices to detect the progression to AD subsequent to TBI. FY15 CSRA Focus Areas: In addition to addressing one or more of the specified FY15 Overarching Challenges, applications should also address at least one of the following FY15 Focus Areas in support of the FY15 Overarching Challenges. An application that proposes research outside of the FY15 Focus Areas is acceptable, as long as the applicant provides a strong rationale. Genomics/Proteomics/Bioinformatics: Studies or technologies (e.g., genetic, proteomic, and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD. In addition, relevant technologies or tests may be considered under this focus area. Pathology of Tau: Novel research and technologies dedicated to unraveling the basic pathological mechanisms of Tau associated with TBI and AD. Roles of Non-Neuronal Cells in TBI/AD Pathogenesis: Technologies, tests, studies, or devices that will examine the roles of astrocytes (or other non-neuronal cells) in AD neurodegeneration due to TBI. Novel Target Identification: Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents. The following is specifically discouraged under the FY15 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or U.S. Food and Drug Administration (FDA)-approved drugs or medicines.

High